Serum resistin as a novel marker of erythropoietin resistance in nondiabetic patients on hemodialysis.

@article{Chang2011SerumRA,
  title={Serum resistin as a novel marker of erythropoietin resistance in nondiabetic patients on hemodialysis.},
  author={Jong Hee Chang and Ji Yong Jung and Hyun Hee Lee and Wookyung Chung and 주권욱 and Sejoong Kim},
  journal={The Tohoku journal of experimental medicine},
  year={2011},
  volume={224 4},
  pages={
          281-5
        }
}
The use of higher erythropoietin (EPO) doses is associated with an increased risk of an adverse outcome and increased mortality in patients with renal failure. Resistin is related to heart disease, and may contribute to an increased atherosclerotic risk. We hypothesized that a link between resistin and EPO responsiveness may exist. We therefore investigated the relationship between resistin and the EPO resistance index (ERI) in nondiabetic hemodialysis (HD) patients. Fifty-seven patients… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Resistin and ERI in HD Patients 285 the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis

G. Cohen, W. H. Horl
  • 2009
VIEW 1 EXCERPT

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2008
VIEW 2 EXCERPTS